Share this article
NEW YORK, Feb. 10, 2021 /PRNewswire/ --
Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters' over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Scopus intends to use the total proceeds of the follow-on public offering, including the proceeds from the exercise of the over-allotment option, principally for further development of the company's lead drug candidate, including in combination with checkpoint inhibitors.